Loading
A 2025 review that weighs the laboratory promise against the absence of human trials and concludes that clinicians should counter misinformation while supporting proper trials.
The review finds that in vitro and animal studies show anticancer effects through Wnt/beta-catenin and Akt/mTOR signalling, but that clinical evidence in humans is limited, with no large randomised controlled trials confirming benefit (Patel review 2025). It notes that observational studies and case reports show the risks of self-medication driven by social media, which has led to toxicity in some oncology patients, and calls the gap between preclinical and clinical evidence a critical translational gap (Patel review 2025).
The clearest recent statement of where the evidence stands: promising in a dish, untested in people, and already causing harm through self-dosing.
Shares Off-label, Ivermectin, Misinformation and unproven therapies.
Shares Off-label, Fenbendazole, ivermectin and other internet 'repurposed cures', Ivermectin, Misinformation and unproven therapies.
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Ivermectin, Misinformation and unproven therapies.
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Ivermectin, Misinformation and unproven therapies.
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Preclinical, Ivermectin.
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Ivermectin, Misinformation and unproven therapies.
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Ivermectin, Misinformation and unproven therapies.
Shares Off-label, Ivermectin, Misinformation and unproven therapies.